Catalyst Pharmaceuticals Submits New Drug Application to FDA for Firdapse to Treat LEMS
![](https://strongly.mda.org/assets/uploads/2018/04/ClinicalTrial01_1030x300_acf_cropped.jpg)
Catalyst Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug amifampridine phosphate (brand name Firdapse) for the treatment of people with Lambert-Eaton myasthenic syndrome (LEMS). The FDA has 60 days to determine whether the NDA is complete and acceptable for filing. If the FDA . . .